From: Prevalence, risk, and outcome of deep vein thrombosis in acute respiratory distress syndrome
Characteristic | Total | DVT | Non-DVT | P value |
---|---|---|---|---|
(N = 225) | (N = 90) | (N = 135) |  | |
Age (years) | 66 ± 17 | 70 ± 13 | 63 ± 18 | <  0.001 |
Male, n (%) | 144 (64.0) | 52 (57.8) | 92 (68.1) | 0.112 |
BMI | 24.1 (21.6, 26.8) | 24.0 (20.8, 26.0) | 24.2 (22.0, 27.2) | 0.146 |
Direct ARDS | ||||
 Pneumonia | 96 (86.5) | 40 (90.9) | 56 (83.6) | 0.412 |
 Aspiration | 15 (13.5) | 4 (9.1) | 11 (16.4) |  |
Indirect ARDS | ||||
 Non-pulmonary sepsis | 81 (71.1) | 33 (71.7) | 48 (70.6) | 0.894 |
 Pancreatitis | 33 (28.9) | 13 (28.3) | 20 (29.4) |  |
Bedridden time (days) | 8 (4, 15) | 10 (5, 18) | 7 (4, 15) | 0.216 |
Caprini score | 7 (5, 9) | 7 (5, 10) | 7 (5, 9) | 0.135 |
Padua prediction score | 6 (5, 6) | 6 (5, 8) | 5 (5, 6) | 0.023 |
APACHE II score | 23 (19, 28) | 24 (20, 28) | 23 (18, 29) | 0.596 |
SOFA score | 8 (5, 10) | 7 (5, 9) | 8 (5, 11) | 0.622 |
Laboratory data | ||||
 White blood cells (×109/L) | 16.9 (12.0, 21.4) | 16.5 (13.4, 21.0) | 17.1 (11.6, 22.6) | 0.733 |
 Neutrophils (×109/L) | 14.5 (10.4, 19.7) | 14.7 (11.4, 19.3) | 14.4 (9.9, 20.1) | 0.709 |
 Platelets (×109/L) | 183.0 (101.0, 253.5) | 196.5 (124.3, 263.3) | 172.0 (84.0, 253.0) | 0.141 |
 C-reactive protein (mg/L) | 120.0 (89.4, 120.0) | 120.0 (82.0, 120.0) | 120.0 (92.5, 120.0) | 0.471 |
 Procalcitonin (ng/mL) | 5.6 (2.0, 16.2) | 12.7 (3.4, 21.5) | 3.5 (1.5, 10.3) | < 0.001 |
 Serum creatinine (μmol/L) | 116.7 (66.6, 209.5) | 95.1 (58.8, 165.5) | 125.6 (70.6, 250.3) | 0.007 |
 D-dimer (μg/ml) | 1.9 (0.9, 3.8) | 2.1 (0.9, 5.0) | 1.8 (0.9, 3.3) | 0.070 |
 PaO2 /FiO2 | 158 (103, 199) | 137 (87, 179) | 172 (116, 209) | 0.002* |
 Mild, n (%) | 54 (24.0) | 14 (15.6) | 40 (29.6) | 0.026# |
 Moderate, n (%) | 116 (51.6) | 48 (53.3) | 68 (50.4) |  |
 Severe, n (%) | 55 (24.4) | 28 (31.1) | 27 (20.0) |  |
Treatments | ||||
 Glucocorticoid therapy, n (%) | 51 (22.7) | 22 (24.4) | 29 (21.5) | 0.603 |
 Immunoglobulin, n (%) | 5 (2.2) | 2 (2.2) | 3 (2.2) | 1.000 |
 Sedative therapy, n (%) | 96 (42.7) | 50 (55.6) | 46 (34.1) | 0.001 |
 Vasoactive agent therapy, n (%) | 55 (24.4) | 25 (27.8) | 30 (22.2) | 0.342 |
 CRRT, n (%) | 33 (14.7) | 10 (11.1) | 23 (17.0) | 0.218 |
 CVC, n (%) | 125 (55.6) | 55 (61.1) | 70 (51.9) | 0.171 |
 IMV, n (%) | 122 (54.2) | 66 (73.3) | 56 (41.5) | < 0.001 |
 Length of IMV (days) | 3 (2, 7) | 3 (2, 6) | 3 (2, 8) | 0.543 |
 Length of IMV ≥ 3 days, n (%) | 80 (65.6) | 43 (65.2) | 37 (66.1) | 0.915 |
 VTE prophylaxis, n (%) | 135 (60.0) | 50 (55.6) | 85 (63.0) | 0.267 |
 LMWH, n (%) | 108 (48.0) | 39 (43.3) | 69 (51.1) | 0.253 |
 LMWH + physical prophylaxis, n (%) | 75 (33.5) | 29 (32.6) | 46 (34.1) | 0.817 |
 Physical prophylaxis only, n (%) | 23 (10.3) | 9 (10.1) | 14 (10.4) | 0.950 |
ICU length of stay (days) | 11 (6, 24) | 12 (5, 24) | 11 (6, 26) | 0.563 |
Hospital length of stay (days) | 19 (12, 32) | 20 (11, 32) | 19 (12, 31) | 0.816 |
Mortality, n (%) | 77 (34.2) | 45 (50.0) | 32 (23.7) | < 0.001 |